glimepiride has been researched along with Apoplexy in 5 studies
glimepiride: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor in clinical use against type 2 diabetes." | 5.39 | The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. ( Darlöf, E; Darsalia, V; Klein, T; Nyström, T; Olverling, A; Ortsäter, H; Patrone, C; Sjöholm, Å; Wolbert, P, 2013) |
| "Using nationwide administrative Danish registries, we followed all individuals without prior stroke or myocardial infarction who initiated metformin and an IS from 1997 through 2009." | 3.81 | Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study. ( Andersson, C; Fosbøl, EL; Gislason, G; Køber, L; Mogensen, UM; Scheller, NM; Schramm, TK; Torp-Pedersen, C; Vaag, A, 2015) |
| " We compared the effects of three SU medications and initial SU doses on adverse glycemic and cardiovascular events among NH residents." | 1.91 | Comparative safety of sulfonylureas among U.S. nursing home residents. ( Berry, SD; Hayes, KN; Munshi, MN; Riester, MR; Zullo, AR, 2023) |
| "Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor in clinical use against type 2 diabetes." | 1.39 | The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. ( Darlöf, E; Darsalia, V; Klein, T; Nyström, T; Olverling, A; Ortsäter, H; Patrone, C; Sjöholm, Å; Wolbert, P, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zullo, AR | 2 |
| Riester, MR | 2 |
| Hayes, KN | 2 |
| Munshi, MN | 2 |
| Berry, SD | 2 |
| Cho, EH | 1 |
| Han, K | 1 |
| Kim, B | 1 |
| Lee, DH | 1 |
| Shannon, RP | 1 |
| Mogensen, UM | 1 |
| Andersson, C | 1 |
| Fosbøl, EL | 1 |
| Schramm, TK | 1 |
| Vaag, A | 1 |
| Scheller, NM | 1 |
| Torp-Pedersen, C | 1 |
| Gislason, G | 1 |
| Køber, L | 1 |
| Darsalia, V | 1 |
| Ortsäter, H | 1 |
| Olverling, A | 1 |
| Darlöf, E | 1 |
| Wolbert, P | 1 |
| Nyström, T | 1 |
| Klein, T | 1 |
| Sjöholm, Å | 1 |
| Patrone, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From the Health Insurance Review and Assessment Service Database[NCT05817097] | 22,119 participants (Anticipated) | Observational | 2023-08-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 other studies available for glimepiride and Apoplexy
| Article | Year |
|---|---|
Comparative safety of sulfonylureas among U.S. nursing home residents.
Topics: Aged; Female; Glipizide; Glyburide; Humans; Hypoglycemia; Male; Medicare; Myocardial Infarction; Nur | 2023 |
Comparative safety of sulfonylureas among U.S. nursing home residents.
Topics: Aged; Female; Glipizide; Glyburide; Humans; Hypoglycemia; Male; Medicare; Myocardial Infarction; Nur | 2023 |
Comparative safety of sulfonylureas among U.S. nursing home residents.
Topics: Aged; Female; Glipizide; Glyburide; Humans; Hypoglycemia; Male; Medicare; Myocardial Infarction; Nur | 2023 |
Comparative safety of sulfonylureas among U.S. nursing home residents.
Topics: Aged; Female; Glipizide; Glyburide; Humans; Hypoglycemia; Male; Medicare; Myocardial Infarction; Nur | 2023 |
Gliclazide monotherapy increases risks of all-cause mortality and has similar risk of acute myocardial infarction and stroke with glimepiride monotherapy in Korean type 2 diabetes mellitus.
Topics: Adult; Aged; Asian People; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agent | 2020 |
DPP-4 inhibition and neuroprotection: do mechanisms matter?
Topics: Animals; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; L | 2013 |
Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
Topics: Aged; Carbamates; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Drug Therapy, Combina | 2015 |
The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride.
Topics: Animals; Diabetes Mellitus, Experimental; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Hypoglyc | 2013 |